Polymer Nanoparticle Compositions for NF1 Treatment
Summary
The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.
What changed
The USPTO published a patent application for polymer nanoparticle compositions designed to deliver nucleic acids for treating NF1 (Neurofibromatosis Type 1). Application No. 19348578, filed October 2, 2025, and published April 2, 2026, discloses block copolymer nanoparticle technology for in vivo therapeutic delivery. The CPC classifications include A61K 9/5138 (nanoparticles), A61K 31/7088 (nucleic acids), and A61P 25/00 (nervous system diseases).
This publication is informational only and does not create compliance obligations. Pharmaceutical companies and researchers developing NF1 therapies may wish to review this application to assess potential freedom-to-operate considerations or avoid prior art conflicts.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF USING POLYMER NANOPARTICLE COMPOSITIONS FOR TREATING A DISEASE
Application US20260090998A1 Kind: A1 Apr 02, 2026
Inventors
Cherry Gupta, Caleb T. Hillrich, Ashlee J. Colbert, Emma K. Schmitz, Joseph Geers, Molly Kaufman, Daniel Garbark, Danielle J. Huk, Matthew Neal, Deeann Wallis, Robert Kesterson, Erik Westin
Abstract
The disclosure relates to methods of using block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to methods of using polymer nanoparticles for delivering nucleic acids for treating NF1.
CPC Classifications
A61K 9/5138 A61K 31/7088 A61P 25/00
Filing Date
2025-10-02
Application No.
19348578
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Therapeutics (A61P) publishes new changes.